Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic.

Interleukin-1 receptor antagonist (IL-1Ra) has been evaluated for the intraarticular treatment of osteoarthritis. Such administration of proteins may have limited utility because of their rapid clearance and short half-life in the joint. The fusion of a drug to elastin-like polypeptides (ELPs) promotes the formation of aggregating particles that form a "drug depot" at physiologic temperatures, a phenomenon intended to prolong the presence of the drug. The purpose of this study was to develop an injectable drug depot composed of IL-1Ra and ELP domains and to evaluate the properties and bioactivity of the recombinant ELP-IL-1Ra fusion protein.

Full Text

Duke Authors

Cited Authors

  • Shamji, MF; Betre, H; Kraus, VB; Chen, J; Chilkoti, A; Pichika, R; Masuda, K; Setton, LA

Published Date

  • November 2007

Published In

Volume / Issue

  • 56 / 11

Start / End Page

  • 3650 - 3661

PubMed ID

  • 17968946

International Standard Serial Number (ISSN)

  • 0004-3591

Digital Object Identifier (DOI)

  • 10.1002/art.22952

Language

  • eng

Citation Source

  • PubMed